Search hospitals > Missouri > Kansas City
Veterans Affairs Medical Center - Kansas City
Claim this profileKansas City, Missouri 64128
Global Leader in Lung Cancer
Global Leader in Prostate Cancer
Conducts research for Pancreatic Cancer
Conducts research for Leukemia
Conducts research for Colorectal Cancer
247 reported clinical trials
11 medical researchers
Summary
Veterans Affairs Medical Center - Kansas City is a medical facility located in Kansas City, Missouri. This center is recognized for care of Lung Cancer, Prostate Cancer, Pancreatic Cancer, Leukemia, Colorectal Cancer and other specialties. Veterans Affairs Medical Center - Kansas City is involved with conducting 247 clinical trials across 408 conditions. There are 11 research doctors associated with this hospital, such as Chao H. Huang, Suman Kambhampati, Prateek Sharma, MD, and Ajay Bansal.Area of expertise
1Lung Cancer
Global LeaderStage IV
Stage I
Stage II
2Prostate Cancer
Global LeaderStage IV
Stage II
Stage I
Top PIs
Chao H. HuangUniversity of Kansas Health System Saint Francis Campus6 years of reported clinical research
Expert in Lung Cancer
Expert in Non-Small Cell Lung Cancer
22 reported clinical trials
35 drugs studied
Suman KambhampatiResearch Medical Center6 years of reported clinical research
Studies Multiple Myeloma
Studies Acute Myelogenous Leukemia
16 reported clinical trials
33 drugs studied
Prateek Sharma, MDKansas City VA Hospital2 years of reported clinical research
Studies Acid Reflux
Studies Barrett's Esophagus
10 reported clinical trials
15 drugs studied
Ajay BansalUniversity of Kansas Cancer Center2 years of reported clinical research
Studies Barrett's Esophagus
Studies Esophageal Adenocarcinoma
7 reported clinical trials
9 drugs studied
Clinical Trials running at Veterans Affairs Medical Center - Kansas City
Prostate Cancer
Bladder Cancer
Lung Cancer
Lymphoma
Pancreatic Cancer
Heart Failure
Colorectal Cancer
Cancer
Chronic Lymphocytic Leukemia
Esophageal cancer
High Dose Testosterone
for Prostate Cancer
This study will determine whether the presence of DNA repair deficiency in the form of alterations in the genes ATM, CDK12 or CHEK2 predicts for a high likelihood of responding to the use of intermittent high dose testosterone. This therapy may result in responses in tumors which are genetically unstable because of DNA repair deficiency and this is a prospective study to test that hypothesis
Recruiting3 awards Phase 2
Blood Sample Collection
for Cancer Detection
This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in the laboratory may help researchers develop tests for the early detection of cancers.
Recruiting1 award N/A9 criteria
Carboplatin vs Olaparib
for Prostate Cancer
This is an unblinded, randomized clinical study comparing the efficacy of DNA damaging chemotherapy using carboplatin, to standard of care therapy for patients who have metastatic castrate resistant prostate cancer. This trial will use olaparib or carboplatin as initial therapy with crossover to the alternate or second-line drug after first progression for patients with tumors containing BARD1, BRCA1, BRCA2, BRIP1, CHEK1, FANCL, PALB2, RAD51B, RAD51C, RAD51D, or RAD54L inactivating mutations. Participants are randomized (1:1) and receive either carboplatin (AUC 5, IV) every 21 days, first or olaparib taken orally (300 mg), twice daily in 28 day cycles, until intolerance, complete response, or progression by Prostate Cancer Working Group 3 (PCWG3) criteria. Participants then crossover from the first-line therapy to the second-line therapy with the opposite study medication and receive treatment to intolerance or progression (whichever is first). Enrolled participants will be allowed to crossover to second line therapy if they continue to meet initial eligibility criteria, and at least three weeks have elapsed since last administration of either carboplatin or olaparib. Throughout the study, safety and tolerability will be assessed. Progression will be evaluated with bone scan, CT of the abdomen/pelvis, or MRI and PSA as per PCWG3 criteria.
Recruiting1 award Phase 2
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Veterans Affairs Medical Center - Kansas City?
Veterans Affairs Medical Center - Kansas City is a medical facility located in Kansas City, Missouri. This center is recognized for care of Lung Cancer, Prostate Cancer, Pancreatic Cancer, Leukemia, Colorectal Cancer and other specialties. Veterans Affairs Medical Center - Kansas City is involved with conducting 247 clinical trials across 408 conditions. There are 11 research doctors associated with this hospital, such as Chao H. Huang, Suman Kambhampati, Prateek Sharma, MD, and Ajay Bansal.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.